Abstract
Lemborexant (DAYVIGO (TM)) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 an......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
